Skip to main content
Premium Trial:

Request an Annual Quote

OGS Extends Research Collaboration with Pfizer for Another Year

NEW YORK, Dec. 14 – Oxford GlycoSciences has extended for another year a proteomics agreement with Pfizer to discover protein biomarkers and potential drug targets for Alzheimer’s disease and atherosclerosis, OGS said Friday.

Under the terms of the renewed agreement, OGS of Oxford, UK, will continue to use its proteomics technology to identify biomarkers in areas of interest to Pfizer. In exchange, Pfizer will provide additional research funding. 

The deal, which was first penned in 1998, was last extended one year ago. At the time Pfizer also took a small stake in OGS.

Pfizer has also renewed its licenses to the OGS human serum and cerebrospinal fluid expression databases and to PC Rosetta, a data analysis software tool. 

OGS has the right to commercialize any diagnostic products arising from the collaboration.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.